Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Diabetes Care
|
August 27, 2016
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Giuseppe Daniele, Juan Xiong, Carolina Solis-Herrera, et al.
Diabetes/Metabolism Research and Reviews
|
April 12, 2019
Exenatide modulates visual cortex responses
Paola Binda, Roy Eldor, Claudia Huerta, et al.
Cardiovascular Diabetology
|
June 25, 2017
Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings
Rafael Y Brzezinski, Inbal Etz-Hadar, Ayelet Grupper, et al.
BMC Geriatrics
|
August 24, 2019
The effect of circuit resistance training, empagliflozin or "vegeterranean diet" on physical and metabolic function in older subjects with type 2 diabetes: a study protocol for a randomized control trial (CEV-65 trial)
Assaf Buch, Roy Eldor, Ofer Kis, et al.
Diabetes Care
|
August 5, 2016
Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects
Roy Eldor, Giuseppe Daniele, Claudia Huerta, et al.
Diabetes/Metabolism Research and Reviews
|
May 24, 2020
Improving blood glucose level predictability using machine learning
Yonit Marcus, Roy Eldor, Mariana Yaron, et al.
Journal of Diabetes Science and Technology
|
January 30, 2024
Identifying Diabetes Related-Complications in a Real-World Free-Text Electronic Medical Records in Hebrew Using Natural Language Processing Techniques
Mor Saban, Miri Lutski, Inbar Zucker, et al.
The Journal of Clinical Investigation
|
January 28, 2014
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, et al.
Diabetes, Obesity & Metabolism
|
May 17, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial
Philip D Home, Raymond L H Lam, Wendy L Carofano, et al.
Diabetes, Obesity & Metabolism
|
December 22, 2017
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Richard E Pratley, Roy Eldor, Annaswamy Raji, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Diabetes Care
|
August 27, 2016
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Giuseppe Daniele, Juan Xiong, Carolina Solis-Herrera, et al.
Diabetes/Metabolism Research and Reviews
|
April 12, 2019
Exenatide modulates visual cortex responses
Paola Binda, Roy Eldor, Claudia Huerta, et al.
Cardiovascular Diabetology
|
June 25, 2017
Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings
Rafael Y Brzezinski, Inbal Etz-Hadar, Ayelet Grupper, et al.
BMC Geriatrics
|
August 24, 2019
The effect of circuit resistance training, empagliflozin or "vegeterranean diet" on physical and metabolic function in older subjects with type 2 diabetes: a study protocol for a randomized control trial (CEV-65 trial)
Assaf Buch, Roy Eldor, Ofer Kis, et al.
Diabetes Care
|
August 5, 2016
Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects
Roy Eldor, Giuseppe Daniele, Claudia Huerta, et al.
Diabetes/Metabolism Research and Reviews
|
May 24, 2020
Improving blood glucose level predictability using machine learning
Yonit Marcus, Roy Eldor, Mariana Yaron, et al.
Journal of Diabetes Science and Technology
|
January 30, 2024
Identifying Diabetes Related-Complications in a Real-World Free-Text Electronic Medical Records in Hebrew Using Natural Language Processing Techniques
Mor Saban, Miri Lutski, Inbar Zucker, et al.
The Journal of Clinical Investigation
|
January 28, 2014
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, et al.
Diabetes, Obesity & Metabolism
|
May 17, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial
Philip D Home, Raymond L H Lam, Wendy L Carofano, et al.
Diabetes, Obesity & Metabolism
|
December 22, 2017
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Richard E Pratley, Roy Eldor, Annaswamy Raji, et al.
Page
of 7